1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 13 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2015Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literatureChan, D.; Pavlakis, N.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Segelov, E.; Rosell, R.
2013Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factorsClarke, S.; Karapetis, C.; Gibbs, P.; Pavlakis, N.; Desai, J.; Michael, M.; Tebbutt, N.; Price, T.; Tabernero, J.
2012Impact of age on choice of chemotherapy and outcome in advanced colorectal cancerKhattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2011Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b studyKotasek, D.; Tebbutt, N.; Desai, J.; Welch, S.; Siu, L.; McCoy, S.; Sun, Y.; Johnson, J.; Adewoye, A.; Price, T.
2012Management of advanced gastric cancerPrice, T.; Shapiro, J.; Segelov, E.; Karapetis, C.; Pavlakis, N.; Van Custem, E.; Shah, M.; Kang, Y.; Tebbutt, N.

Discover